Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myelogenous Leukemia
Study results from University of Massachusetts provide new insights into acute myelogenous leukemia
March 30th, 2008
According to a study from the United States, "Purpose of review For decades, retinoic acid has been known to alter the proliferation and differentiation of myeloid cells. Currently, retinoic acid is a front-line agent in the treatment of certain forms of acute myelogenous leukemia." "In this review, we focus on recent advances in our understanding of the mechanisms by which retinoids affect growth and proliferation of myeloid cells and contribute to the pathogenesis of leukemia. We have not attempted to summarize the related clinical literature. Recent findings The past 2 years have yielded important understanding of the mechanisms by which retinoids and their nuclear...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-30)
|
